Experience of Clinical Diagnosis and Drug Treatment of Bacterial Pneumonia  

作　　者：CHENWeiwei 

机构地区：[1]Department of Respiratory and Critical Care Medicine, People's Hospital of Pingba District, Anshun Guizhou 561100, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第6期113-116,共4页

摘　　要：Objective: to study and analyze the clinical diagnosis and drug treatment experience of bacterial pneumonia. Methods: into our hospital from March 2020 to October 202140 cases of bacterial pneumonia patients, random number table method is divided into research group, control group, each 20 cases, and both groups of patients received serology and sputum detection, control group with amoxicillin administration, study group patients with amoxicillin clavulanate potassium and ambroxol intervention, while drug treatment, two groups of patients laboratory examination index improvement, treatment effect, lung function improvement, disease control, etc. Results: the serum procalcitonin and C reactive protein in the study group were lower than the control group;the total response rate was higher than the control group;the volume and forced lung capacity were higher than the control group, and the regression time of main symptoms were shorter than that of the control group;the differences were significant (P <0.05). Conclusion: the diagnosis of bacterial pneumonia depends on the combined detection of serology and sputum, and it is helpful to improve the effect of disease control and improve lung function.

关 键 词：bacterial pneumonia clinical diagnosis potassium amoxicillin-clavulanate AMBROXOL 

分 类 号：R[医药卫生]